A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Clinical trial NCT04927884 · TERMINATED

Trial details

NCT number: NCT04927884
Sponsor: ImmunityBio, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Triple Negative Breast Cancer

Start date: 2021-09-08
Primary completion: 2022-09-13
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.